Does testosterone therapy cause heart problems? The fear that it causes heart attacks comes from two studies that are now more than a decade old and from a decade of headlines built on them. The largest randomized trial ever run on the question, published in the New England Journal of Medicine in 2023, did not find the harm those headlines promised. What it found and what it left open are worth knowing precisely because the honest answer shapes who should start therapy and how it should be monitored.

Key takeaways
  • The TRAVERSE trial of over 5,000 men found no increase in major adverse cardiac events over roughly two years of therapy.
  • Two older studies from 2013 to 2015 drove the fear and both had design problems that later analyses exposed.
  • Modest excess signals in TRAVERSE, including atrial fibrillation, pulmonary embolism and acute kidney injury, are real and belong in the consent conversation.
  • Hematocrit, blood pressure and ApoB are the numbers that make testosterone therapy safe or unsafe. All three are on our quarterly panel.
  • The fee never changes with the dose, so monitoring decisions carry no profit motive on our side.

What the fear is made of

Two studies did most of the damage. The first, published in 2013 in JAMA, reported increased cardiac events in older men on testosterone and was later found to have compared dissimilar groups, with its own authors reanalyzing the data after publication and the corrected analysis showing no such signal. The second, the Testosterone in Older Men trial, was halted early after cardiovascular events appeared, but the events clustered in a small subgroup and the trial was designed to measure muscle strength, not cardiac safety.

Between those headlines and 2023 the evidence moved in both directions. Registry studies and meta-analyses pointed at possible benefit in properly selected men, including work by G. V. Rajkumar and colleagues suggesting lower cardiovascular event rates in men whose testosterone was normalized on therapy. What was missing was a randomized trial designed to answer the question directly and in 2023 that trial arrived.

What TRAVERSE actually found

TRAVERSE enrolled more than 5,000 men with confirmed hypogonadism and preexisting or high cardiovascular risk, which is the population where the fear was loudest. Participants received either daily testosterone gel or placebo for roughly two years and the primary endpoint was major adverse cardiac events, a composite of death from cardiovascular causes, nonfatal heart attack and nonfatal stroke.

The result was no significant difference between the groups. Testosterone was not shown to increase major adverse cardiac events in this high-risk population over the two-year window. Several secondary signals did emerge and they deserve plain language rather than a footnote. Men on testosterone had modestly more atrial fibrillation, pulmonary embolism and acute kidney injury and hematocrit rose as expected. Those findings are exactly why screening and monitoring are not paperwork but the safety mechanism itself.

Clinical note

The question is no longer whether testosterone harms the heart at guideline doses. It is whether the workup and the monitoring around it are real.

What makes therapy safe or unsafe in practice

The cardiac-relevant signal on testosterone is hematocrit. Testosterone stimulates red cell production and when hematocrit climbs past threshold the blood thickens and the event risk follows. The Endocrine Society guideline calls for baseline hematocrit before therapy and follow-up measurement during it, with therapy adjusted when the ceiling is crossed. A clinic that never rechecks hematocrit is not being relaxed about safety. It is removing the safety mechanism.

Blood pressure, the lipid panel and ApoB carry the rest of the picture, because most men considering testosterone therapy carry metabolic risk alongside it. The TRAVERSE cohort was chosen for cardiovascular risk precisely because that is the real-world population and our quarterly Cardiometabolic Optimization Panel is built around the same reality. On every draw it includes Apolipoprotein B (ApoB), a Lipid Panel, Standard, Hs-CRP, Fasting Insulin, Hemoglobin A1c (HbA1c), Lipoprotein (A), TSH With Reflex To Free T4 and CBC (Includes Differential And Platelets), which is the set of numbers that either supports the dose you are on or argues against it.

Dose discipline is the other half. We titrate to the lowest effective dose that restores symptoms and holds markers in line, then recheck every 90 days. That is not caution as a marketing posture. It is the same dose minimization the guidelines describe and the flat fee means our revenue is identical whether your dose rises or falls, so the titration decision has no profit motive behind it.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Who should not start or should wait

Honest safety writing names the exclusion list rather than promising universal safety. Men with active or recent cardiovascular events, uncontrolled heart failure, elevated hematocrit from any cause, untreated severe sleep apnea or an active near-term desire for fertility should either wait or be treated for the underlying condition first. Testosterone suppresses sperm production, so fertility intentions belong in the first conversation, not the third.

Our own clinical protocols ask exactly these questions before acceptance and the $598 hold at sign-up is charged only once a clinician has accepted you into care, which is the structural answer to clinics that sell first and screen later, if at all.

What this means for the longevity reader

For the Concierge Longevity Optimizer, the honest framing is this. The two-year randomized evidence does not show cardiac harm at guideline doses with monitoring and the long-term benefit question remains open, which means testosterone is neither the elixir the optimization industry sells nor the danger the headlines implied. It is a therapy with a real indication, real exclusions and a monitoring burden that is not optional.

That monitoring burden is exactly what a membership that includes quarterly labs absorbs. In a per-visit system the rechecks get skipped because each one costs a copay and a day off work. In the membership they are the product, four audits a year, with the clinician who prescribed reading the results.

What the membership costs, stated plainly

The Cardiometabolic Optimization Membership is one flat $299 per month covering the clinical relationship and four quarterly Biomarker Audits a year. It starts with a two month commitment paid as a single $598 hold covering the first two months together, charged only once a clinician accepts you into care. If no clinician can accept you, the hold is released and you are never charged. Once accepted, the first two months are non-refundable. From month three the membership is month to month and you can cancel anytime.

Medication is a separate charge and it never flows through us. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on that transaction. There is no molecule upcharge and no dose upcharge, ever. One flat fee for the doctor. Zero markup on the medicine. The eligibility check is free and takes a few minutes.

Frequently Asked Questions

Does testosterone therapy cause heart problems?

The TRAVERSE trial in the New England Journal of Medicine found no increase in major adverse cardiac events among men on testosterone for about two years. Testosterone is not established as harmful to the heart at guideline doses and the honest open question is long-term benefit, which is why monitoring and ApoB control still carry the risk reduction.

What was the TRAVERSE trial?

A randomized trial of over 5,000 men with hypogonadism and preexisting or high cardiovascular risk, published in the New England Journal of Medicine in 2023. Testosterone gel versus placebo for roughly two years showed no significant difference in major adverse cardiac events and modestly more atrial fibrillation, pulmonary embolism and acute kidney injury in the testosterone group.

Why did older studies raise the alarm?

Two widely reported studies around 2013 to 2015 suggested increased cardiac events, but both had design problems. One compared dissimilar groups and reanalyzed its own data after publication. The other was halted early with events clustered in a small subgroup. Neither was designed to test causation.

Who should be cautious with testosterone?

Men with active or recent cardiovascular disease, uncontrolled heart failure, a high hematocrit, untreated sleep apnea or an active desire for fertility in the near term. That list is exactly why a real clinical workup with labs precedes any prescription.

What should be monitored on testosterone?

Hematocrit, because testosterone raises it and a high hematocrit is the actual cardiac-relevant signal, plus blood pressure, the lipid panel and ApoB at each quarterly audit. Therapy should be adjusted or paused when hematocrit exceeds threshold.

Is testosterone therapy safe for the heart?

At guideline doses with proper screening and monitoring, the current evidence does not show cardiac harm over the two-year horizon studied and the long-term benefit question remains open. Safety depends on the workup, the dose discipline and the monitoring cadence, not the molecule.

Does the GoodLife Health fee change with my dose?

No. The membership is a flat $299 per month for the doctor and four quarterly Biomarker Audits and any prescription is billed by your pharmacy separately at pharmacy cost with zero markup.

One last thing

The cardiology question about testosterone is really a question about the system prescribing it. A therapy with a hematocrit ceiling, a blood pressure line and an ApoB target is either monitored or it is a gamble and the system that skips the rechecks because each one bills separately is the system that produced the fear in the first place. The membership makes the rechecks automatic because they are already paid for. That is the whole safety story and the eligibility check is where it starts.

Related Guides

References

  1. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE), New England Journal of Medicine, 2023. nejm.org
  2. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2018. doi.org/10.1210/jc.2018-00229